KAPA
Kairos Pharma·AMEX
--
--(--)
--
--(--)
KAPA fundamentals
During Q4 2025, Kairos Pharma (KAPA) reported revenue of --, a YoY change of 0.00%. Net income was -1.36M, a YoY change of -39.29%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Sales and Services Revenue | -- -- | -- -- | 0 -- | -- -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | 0 -- | -- -- |
Operating Expenses | 120.00K -- | 124.00K -- | 180.00K -- | 126.00K -- | 212.00K +76.67% | 287.00K +131.45% | 1.09M +505.00% | 287.00K +127.78% | 222.00K +4.72% | 383.00K +33.45% | 1.45M +32.78% | 1.27M +341.11% | 1.46M +555.86% | 1.44M +274.67% | 1.42M -2.14% | 5.57M -- |
Selling, General and Administrative Expenses | 114.00K -- | 124.00K -- | 132.00K -- | 120.00K -- | 176.00K +54.39% | 254.00K +104.84% | 1.08M +719.70% | 122.00K +1.67% | 159.00K -9.66% | 369.00K +45.28% | 1.27M +17.74% | 773.00K +533.61% | 960.00K +503.77% | 827.00K +124.12% | 877.00K -31.16% | 3.44M -- |
General and Administrative Expenses | -- -- | -- -- | 484.00K -- | -- -- | 176.00K -- | 254.00K -- | 1.08M +123.55% | 122.00K -- | 159.00K -9.66% | 369.00K +45.28% | 1.27M +17.74% | 773.00K +533.61% | 960.00K +503.77% | 827.00K +124.12% | 877.00K -31.16% | 3.44M -- |
Research and Development Expenses | 6.00K -- | -- -- | 48.00K -- | 6.00K -- | 36.00K +500.00% | 33.00K -- | 7.00K -85.42% | 165.00K +2650.00% | 63.00K +75.00% | 14.00K -57.58% | 172.00K +2357.14% | 493.00K +198.79% | 496.00K +687.30% | 608.00K +4242.86% | 538.00K +212.79% | 2.13M -- |
Operating Income | -120.00K -- | -124.00K -- | -180.00K -- | -126.00K -- | -212.00K -76.67% | -287.00K -131.45% | -1.09M -505.00% | -287.00K -127.78% | -222.00K -4.72% | -383.00K -33.45% | -1.45M -32.78% | -1.27M -341.11% | -1.46M -555.86% | -1.44M -274.67% | -1.42M +2.14% | -5.57M -- |
Non-Operating Income (Loss) | -265.00K -- | -110.00K -- | -16.00K -- | -20.00K -- | -24.00K +90.94% | -25.00K +77.27% | -29.00K -81.25% | -36.00K -80.00% | -31.00K -29.17% | -664.00K -2556.00% | 466.00K +1706.90% | 4.00K +111.11% | 34.00K +209.68% | 37.00K +105.57% | 50.00K -89.27% | 125.00K -- |
Other Non-Operating Income (Loss) | -250.00K -- | -90.00K -- | -10.00K -- | -10.00K -- | -10.00K +96.00% | -10.00K +88.89% | -26.00K -160.00% | -20.00K -100.00% | -19.00K -90.00% | -115.00K -1050.00% | -71.00K -173.08% | 0 +100.00% | 0 +100.00% | -- -- | 0 +100.00% | -- -- |
Net Interest Expense | 15.00K -- | 20.00K -- | 6.00K -- | 10.00K -- | 14.00K -6.67% | 15.00K -25.00% | 3.00K -50.00% | 16.00K +60.00% | 12.00K -14.29% | 549.00K +3560.00% | -537.00K -18000.00% | -4.00K -125.00% | -34.00K -383.33% | -37.00K -106.74% | -50.00K +90.69% | -125.00K -- |
Interest Expense | 15.00K -- | 20.00K -- | 6.00K -- | 10.00K -- | 14.00K -6.67% | 15.00K -25.00% | 3.00K -50.00% | 16.00K +60.00% | 12.00K -14.29% | 549.00K +3560.00% | -537.00K -18000.00% | 0 -100.00% | 0 -100.00% | -- -- | 0 +100.00% | -- -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | 0 -- | 4.00K -- | 34.00K -- | 37.00K -- | 50.00K -- | 125.00K -- |
Pretax Income From Continuing Operations | -385.00K -- | -234.00K -- | -196.00K -- | -146.00K -- | -236.00K +38.70% | -312.00K -33.33% | -1.12M -470.41% | -323.00K -121.23% | -253.00K -7.20% | -1.05M -235.58% | -980.00K +12.34% | -1.26M -290.71% | -1.42M -462.06% | -1.40M -33.52% | -1.36M -39.29% | -5.45M -- |
Net Income | -385.00K -- | -234.00K -- | -196.00K -- | -146.00K -- | -236.00K +38.70% | -312.00K -33.33% | -1.12M -470.41% | -323.00K -121.23% | -253.00K -7.20% | -1.05M -235.58% | -980.00K +12.34% | -1.26M -290.71% | -1.42M -462.06% | -1.40M -33.52% | -1.36M -39.29% | -5.45M -- |
Net Income Attributable to Owners of the Company | -385.00K -- | -234.00K -- | -196.00K -- | -146.00K -- | -236.00K +38.70% | -312.00K -33.33% | -1.12M -470.41% | -323.00K -121.23% | -253.00K -7.20% | -1.05M -235.58% | -980.00K +12.34% | -1.26M -290.71% | -1.42M -462.06% | -1.40M -33.52% | -1.36M -39.29% | -5.45M -- |
Net Income Attributable to Common Stockholders | -385.00K -- | -234.00K -- | -196.00K -- | -146.00K -- | -236.00K +38.70% | -312.00K -33.33% | -1.12M -470.41% | -323.00K -121.23% | -253.00K -7.20% | -1.05M -235.58% | -980.00K +12.34% | -1.26M -290.71% | -1.42M -462.06% | -1.40M -33.52% | -1.36M -39.29% | -5.45M -- |
Total Comprehensive Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -2.60M -- | -- -- | -- -- | -- -- | -5.45M -109.26% | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -- -- | -- -- | -- -- | -- -- | -312.00K -- | -1.12M -- | -323.00K -- | -253.00K -- | -- -- | -2.60M -132.83% | -1.26M -290.71% | -1.42M -462.06% | -- -- | -5.45M -109.26% | -- -- |
Basic EPS | -0.04 -- | -0.02 -- | -- -- | -0.01 -- | -0.02 +50.00% | -0.03 -50.00% | -- -- | -0.03 -200.00% | -0.02 -- | -0.1 -233.33% | -0.07 -- | -0.08 -166.67% | -0.08 -300.00% | -0.07 +30.00% | -0.07 -- | -0.3 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -0.02 -- | -0.03 -- | -- -- | -0.03 -- | -0.02 -- | -0.1 -233.33% | -- -- | -0.08 -166.67% | -0.08 -300.00% | -0.07 +30.00% | -- -- | -- -- |
Diluted EPS | -0.04 -- | -0.02 -- | -- -- | -0.01 -- | -0.02 +50.00% | -0.03 -50.00% | -- -- | -0.03 -200.00% | -0.02 -- | -0.1 -233.33% | -- -- | -0.08 -166.67% | -0.08 -300.00% | -0.07 +30.00% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -0.02 -- | -0.03 -- | -- -- | -0.03 -- | -0.02 -- | -0.1 -233.33% | -- -- | -0.08 -166.67% | -0.08 -300.00% | -0.07 +30.00% | -- -- | -- -- |
You can ask Aime
Did Kairos Pharma beat or miss consensus estimates last quarter?What is Kairos Pharma's latest dividend and current dividend yield?What is the revenue and EPS growth rate for Kairos Pharma year over year?What does Kairos Pharma do and what are its main business segments?What factors drove the changes in Kairos Pharma's revenue and profit?What were the key takeaways from Kairos Pharma’s earnings call?What is Kairos Pharma's gross profit margin?What were the key takeaways from Kairos Pharma's earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
